Posted by Michael Wonder on 27 Aug 2020
European Commission approves Blenrep (belantamab mafodotin) for the treatment of patients with relapsed and refractory multiple myeloma
26 August 2020 - Marketing authorisation follows the recent US approval of Blenrep.
GlaxoSmithKline today announced the European Commission has granted conditional marketing authorisation for Blenrep (belantamab mafodotin) as monotherapy for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Blenrep is a first-in-class humanised anti-BCMA (B-cell maturation antigen) treatment for these patients whose disease has progressed despite the current standard of care.
